Pharmaxis Ltd (ASX:PXS)

Pharmaxis is an established pharmaceutical research company working on new therapies to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis, inflammatory bowel diseases and cancer.

Bronchitol®

Bronchitol is approved for the treatment of certain patients with cystic fibrosis to help them clear mucus from their lungs.

Bronchitol is dry powder mannitol which is inhaled twice daily using a small handheld device. Bronchitol works by rehydrating the airway/lung surface and promoting a productive cough. Clinical trials have shown that Bronchitol helps to increase mucus clearance, and improve the lung function and the quality of life of people living with cystic fibrosis.

(click here for more information)


Aridol®

Pharmaxis' first commercial product, Aridol is an innovative lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. Patients inhale increasing doses of Aridol via a simple hand-held device. Respiratory clinicians administering the test measure the patient's lung function to identify airway inflammation which can assist doctors in providing appropriate asthma treatment. Aridol is approved for sale in Australia, major European countries and South Korea. It is the first and only approved Europe-wide approved bronchial challenge test and the world's first approved indirect challenge test for asthma, a condition which affects 52 million people worldwide. Aridol is used in investigator-sponsored clinical trials worldwide. It has also been included in both international and Australian official guidelines for managing asthma. Bodies and guidelines referencing Aridol include:

• Global Initiative for Asthma (GINA) Report on Global Strategy for Asthma Management and Prevention
• Australian Asthma Management Handbook
• Australian Sports Drug Medical Advisory Committee (ASDMAC)

PRODUCT PIPELINE

Drug Discovery

The objective of Pharmaxis' drug discovery program is to have at least one new drug candidate each year complete formal pre-clinical testing and be phase 1 ready.

(click here for information on this project)

Amine Oxidase Platform

The inhibition of amine oxidase based enzymes has broad potential applications

(click here for information on this project)

Other Pipeline Assets

Orbital® Dry Powder Inhaler

Orbital® Dry Powder Inhaler (DPI) convenient delivery of high drug doses to the lungs.

(click here for more information on this project)

Last updated 12th July 2018

BOARD OF DIRECTORS

Malcolm J McComas
BEc LLB - Independent Chairman

Malcolm has been a member of the Board of Directors since July 2003 and Chairman of the Board since 2012. He is a company director, former investment banker and commercial lawyer. Malcolm is the principal of McComas Capital and was previously a director of investment banking and funds management group Grant Samuel.

Malcolm is a former Managing Director of investment banking at County NatWest and its successor organisation Salomon Smith Barney (now Citigroup). He has held various executive roles with Morgan Grenfell (now Deutsche Bank) in Melbourne, Sydney and London.

Malcolm has worked with many high growth companies across various industry sectors and has experience in equity and debt finance, acquisitions and divestments and privatisations. He has led more than 50 initial public offerings and significant secondary offerings for companies, institutions and governments. Malcolm is Chairman of Fitzroy River Corporation Limited, a director of Saunders International Limited and the Australasian Leukaemia and Lymphoma Group and a senior advisor to CW Downer & Co.  He was the former President of Finsia (the Financial Services Institute of Australia) and previously a director of Consolidated Minerals Limited, Ocean Capital Limited and BC Iron Limited. 

Malcolm is chairman of the Pharmaxis Remuneration and Nomination Committee and a member of the Audit Committee.


Gary J Phillips
B Pharm MBA - Chief Executive Officer

Gary joined the Company in 2003 and was appointed Chief Executive Officer and became a member of the Board of Directors in March 2013. He previously held the positions of Commercial Director and Chief Operating Officer. Gary has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia.

From 1994 to 1998, he was Chief Executive Officer at Ciba Geigy in Hungary (merged to form Novartis in 1996) where he led the successful launch of a portfolio of new products.  After a period of 3 years as an area manager for Novartis responsible for 9 countries in Asia Pacific in 2001 he joined Novartis Australia as Group Company Head and Chief Executive Officer of its Pharmaceutical Division, successfully launching leading oncology and ophthalmology products. Gary holds a BPharm in Pharmacy with honors from Nottingham University in the UK and an MBA from Henley Management College.


William L Delaat
AM BSc - Non-Executive Director

Will has been a member of the Board of Directors since June 2008. He has more than 35 years’ experience in the global pharmaceutical industry, most recently as the Managing Director of the Australian subsidiary of Merck & Co, a position he held from 1997 until his retirement in 2008.

During his career Will has held executive positions in both Europe and Australia for Merck and AstraZeneca. He has a broad depth of experienced in pharmaceutical sales and marketing and has been responsible for numerous international product launches.

Will was Chairman of the pharmaceutical peak body Medicines Australia, and the Pharmaceuticals Industry Council from 2008-2012. He is also Chairman of EnGeneIC Ltd, an unlisted Australian biotech company, and a director of the George Institute for Global Health Board.

Will holds a Bachelor of Science, Physiology & Chemistry, from the University of London.

Will is Chair of the Pharmaxis Audit Committee and a member of the Remuneration and Nomination Committee.


Simon HW Buckingham
BVSc (Hons) PhD - Non-Executive Director

Simon has been a member of the Board of Directors since July 2012. He has over 25 years’ experience in the global pharmaceutical industry across a range of functions and a variety of therapeutic areas. Now based in Sydney, Simon is currently a senior global advisor to Actelion, one of the world’s leading biopharmaceutical companies, and is a director of Actelion Australia. He was President, Global Corporate and Business Development at Actelion from 2005-2011, a position which spanned licensing, M&A, alliance management and corporate strategic planning. Simon served as President, North America and Asia-Pacific at Actelion from 2000-2005, with responsibility for all commercial operations in the region. He was the founding President of Actelion Pharmaceuticals US. From 1998-2000 he worked in sales and marketing for Parke-Davis (now part of Pfizer) in the US and prior to that served in roles in sales, marketing and development at Roche, both in Switzerland and Australia, for 9 years.

Simon is currently a non-executive director of European based Vaxxilon and also of the Can Too Foundation, a non-profit organisation raising funds for cancer research. He holds a Bachelor of Veterinary Science degree from the University of Sydney, a PhD from the University of Melbourne, a Graduate Management Qualification from the AGSM, University of NSW and is a Graduate of the Australian Institute of Company Directors. Simon is a member of the Pharmaxis Audit Committee and the Remuneration & Nomination Committee.


David M McGarvey
BA CA CPA - Company Secretary and Chief Financial Officer

David has been Chief Financial Officer and Company Secretary since December 2002. He is a seasoned CFO with thirty years’ experience building and funding Australian based companies from inception to globally successful enterprises.

From 1998 to 2002 David served as Chief Financial Officer of the Filtration and Separations Division of US Filter. From 1985 to 1997 he served as Chief Financial Officer of Memtec Limited. While at Memtec and US Filter, David oversaw the US listing of the company on the Nasdaq Global Market and the New York Stock Exchange and managed numerous international merger and acquisition transactions. From 1975 to 1985, he held various positions at PriceWaterhouseCoopers.

David holds a BA in Accounting from Macquarie University and was admitted to the Chartered Accountants Australia and New Zealand in 1981 and to the membership of CPA Australia in 1993.


Kathleen M Metters
Non-Executive Director

Dr Kathleen Metters joined the Board of Directors in June 2017 bringing more than 25 years of experience in the discovery and development of novel therapies for treatment of serious diseases. She was formerly the Senior Vice President and Head of Worldwide Basic Research for Merck & Co. with oversight of all the company’s global research projects. In a subsequent role at Merck &Co. she led work on External Discovery and Preclinical Sciences.

Kathleen was President and CEO of biopharmaceutical company Lycera Corp and is currently an independent consultant and senior advisor for Bridge Medicines.

Kathleen graduated with a B.S. in biochemistry from the University of Manchester Institute for Science and Technology, and a Ph.D. from Imperial College of Science and Technology in London.

Dr Metters was appointed to the Company's Scientific Advisory Board in August 2017.


SENIOR MANAGEMENT

Gary J Phillips
B Pharm MBA - Chief Executive Officer

Gary joined the Company in 2003 and was appointed Chief Executive Officer and became a member of the Board of Directors in March 2013. He previously held the positions of Commercial Director and Chief Operating Officer. Gary has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia.

From 1994 to 1998, he was Chief Executive Officer at Ciba Geigy in Hungary (merged to form Novartis in 1996) where he led the successful launch of a portfolio of new products.  After a period of 3 years as an area manager for Novartis responsible for 9 countries in Asia Pacific in 2001 he joined Novartis Australia as Group Company Head and Chief Executive Officer of its Pharmaceutical Division, successfully launching leading oncology and ophthalmology products. Gary holds a BPharm in Pharmacy with honors from Nottingham University in the UK and an MBA from Henley Management College.

David M McGarvey
BA CA CPA - Company Secretary and Chief Financial Officer

David has been Chief Financial Officer and Company Secretary since December 2002. He is a seasoned CFO with thirty years’ experience building and funding Australian based companies from inception to globally successful enterprises.

From 1998 to 2002 David served as Chief Financial Officer of the Filtration and Separations Division of US Filter. From 1985 to 1997 he served as Chief Financial Officer of Memtec Limited. While at Memtec and US Filter, David oversaw the US listing of the company on the Nasdaq Global Market and the New York Stock Exchange and managed numerous international merger and acquisition transactions. From 1975 to 1985, he held various positions at PriceWaterhouseCoopers.

David holds a BA in Accounting from Macquarie University and was admitted to the Chartered Accountants Australia and New Zealand in 1981 and to the membership of CPA Australia in 1993.

Brett Charlton
MBBS PhD - Medical Director

Brett co-founded Pharmaxis in 1998 and has served continuously as the Company’s Medical Director overseeing all aspects of clinical research.

Brett is the author of more than 60 scientific papers with 15 years of experience in clinical trial design and management. He was founding Medical Director of the National Health Sciences Centre and established its Clinical Trials Unit. Prior to joining Pharmaxis he held various positions with the Australian National University, Stanford University, the Baxter Centre for Medical Research, Royal Melbourne Hospital, and the Walter and Eliza Hall Institute.

Brett holds a MBBS with honors from the University of New South Wales and a PhD from the University of New South Wales.

Wolfgang G Jarolimek
BSc PhD - Head of Drug Discovery

Wolfgang joined Pharmaxis in September 2010 as Manager in vitro Pharmacology and was appointed Head Drug Discovery in August 2012.

He has more than 15 years’ experience in pharmaceutical drug discovery and has published more than 20 peer reviewed articles. From 2002 to 2010 Wolfgang was Director of Assay Development and Compound Profiling at the GlaxoSmithKline Center of Excellence in Drug Discovery in Verona, Italy. In addition to chairing early drug discovery efforts locally he also had global responsibilities for ion channel screening and implementing safety-related screening. From 1998 to 2002 he worked at the Neuroscience Center of Merck, Sharp and Dohme in Harlow, England, as Senior Research Scientist in the electrophysiology group. Wolfgang previously spent 8 years as post-doc at the Max-Plank Institute in Munich, Germany; Baylor College of Medicine, Houston, Texas; Rammelkamp Center, Cleveland Ohio; and University of Heidelberg, Germany.

Wolfgang holds a BSc in Pharmacy and a PhD from the University of Saarbrücken, Germany. In 1997 he became Assistant Professor in Physiology at the University of Heidelberg, Germany.

Kristen Morgan
BSc PGDipBusAdmin, MMedSc - Alliance Management

Kristen joined Pharmaxis in August 2008 and now has responsibility for Alliance Management and Medical and Regulatory Affairs.  She has 19 years’ experience in the pharmaceutical industry having previously held a senior role in medical affairs at Sanofi-Aventis, and a commercial sales role at GlaxoSmithKline. Kris holds a BSc from Queensland University (major in pharmacology), a Postgraduate Diploma of Business Administration from Queensland University of Technology and a Masters of Medical Science (Drug Development) from University of New South Wales.

Last updated 12th July 2018

Summary of Issued Securities

Major Shareholders
The top 20 shareholders in Pharmaxis Ltd on 30 June 2018 are:

Note: the above tables are updated after each quarter end

Substantial Shareholders
Pharmaxis has received the following substantial shareholder notices:

Last updated 12th July 2018

Investors, corporate and financial

David McGarvery
Chief Financial Officer & Company Secretary
P | +61 2 9454 7200
E | [email protected] 

Felicity Moffatt
Media Contacts
M| +61 (0) 418 677 701
E | [email protected]  

Gary Phillips
Partner and collaboration contacts
P |  +61 (02) 9454 7200
E |  [email protected]

Clinical trials, product information and medical information
P | Australia Head Office Phone: +61 2 9454 7200
E | [email protected]

Adverse events
E | [email protected]
F | + 61 2 9454 7255

Customer  Information
E | [email protected]

Head Office - Australia



Pharmaxis Ltd
20 Rodborough Road
Frenchs Forest NSW 2086
AUSTRALIA

Mailing Address:
Locked Bag 5015
Frenchs Forest NSW 2086
AUSTRALIA

P | +61 2 9454 7200
F | +61 2 9451 3622
E | [email protected]

Europe
UK Mailing Address
Pharmaxis Pharmaceutical Limited
25 Moorgate, London, EC2R 6AY, England



Last updated 12th July 2018

Directors
Malcolm McComas - Chairman
Gary Phillips - Chief Executive Officer
Simon Buckingham – Non Executive Director
Will Delaat – Non Executive Director
Kathleen Metters - Non Executive Director 

Company Secretary and Chief Financial Officer
David McGarvey
E | [email protected]

Investor relations enquiries
David McGarvey
E | [email protected]

Media enquiries
Felicity Moffatt
E| [email protected]

Partnership and collaboration enquiries
Gary Phillips
E | [email protected]

Registered office
20 Rodborough Road
Frenchs Forest NSW 2086
Australia

Telephone: +61 2 9454 7200
Fax: +61 2 9451 3622
Email: [email protected]
Website: www.pharmaxis.com.au

Securities exchange listings
Pharmaxis shares are listed on the Australian Stock Exchange (Code: PXS)

Pharmaxis American Depositary Receipts are traded on the US over-the-counter market (Code: PXSLY)

Legal advisors
PFM Legal Pty Ltd
Level 7, 257 Clarence Street
Sydney NSW 2000
Australia

Auditor
PricewaterhouseCoopers
Darling Park Tower 2
201 Sussex Street
Sydney NSW 2000
Australia

Banks
Westpac Banking Corporation
HSBC

Share registry
Computershare Investor Services Pty Ltd
Level 3, 60 Carrington Street
Sydney NSW 2000
Australia

Telephone: 1300 855 080
                  +61 (03) 9415 4000
Website: http://www.computershare.com.au

American depositary receipts
BNY Mellon Shareowner Services
P.O. Box 30170

College Station, TX 77842-3170

Telephone: 1-888-BNY-ADRS (1-888-269-2377)

(toll free number for domestic callers)

International: +1 201 680 6825



Last updated 12th July 2018.